Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cambridge Cancer Genomics
AddedMar 17, 2024
UpdatedJul 3, 2026
Cambridge Cancer Genomics

Cambridge Cancer Genomics

Closed

Empowering clinicians with personalized cancer treatment strategies. Join us in Cambridge, UK. Apply now!

Founded
2015
Accelerator
Y Combinator logoY CombinatorS17
Overview
Compare
Fundraising
Employees

Cambridge Cancer Genomics (CCG.ai) empowers clinicians to make personalized treatment strategies for cancer patients. They develop software for data-driven precision oncology and biomarkers indicative of treatment response. Their mission is to ensure each patient receives the right drug at the right time, leveraging clinical and genomic data to transform cancer treatment.

CCG.ai has made significant strides in precision oncology, impacting how oncologists make treatment decisions. By systematically developing data-driven biomarkers, they have enhanced the personalization of cancer therapies. Their work is pivotal in advancing the field of oncology through innovative software solutions.

Cambridge Cancer Genomics - Similar Companies

GenomOncology logo

GenomOncology

genomoncology.com

Onc.AI logo

Onc.AI

onc.ai

Oncobox logo

Oncobox

oncobox.com

Triomics logo

Triomics

triomics.com

OncoPrecision logo

OncoPrecision

oncoprecision.bio

D2G Oncology logo

D2G Oncology

d2g-oncology.com

BostonGene logo

BostonGene

bostongene.com

MyCancerDB logo

MyCancerDB

ennov1.com

Empiri logo

Empiri

empiricancer.com

Data Driven Bioscience logo

Data Driven Bioscience

OmicsChart logo

OmicsChart

omicschart.com

Personalis logo

Personalis

personalis.com

xCures logo

xCures

xcures.com

Clear Gene logo

Clear Gene

cleargene.com

Genomate Health logo

Genomate Health

genomate.health

Cambridge Cancer Genomics - Quick Facts

Who are Cambridge Cancer Genomics' competitors?

Companies similar to Cambridge Cancer Genomics include GenomOncology, Onc.AI, Oncobox and Triomics.

When was Cambridge Cancer Genomics founded?

Cambridge Cancer Genomics was founded in 2015.

When was Cambridge Cancer Genomics' last funding round?

Cambridge Cancer Genomics' most recent funding round was for $120k (USD) in January 2017.

How much has Cambridge Cancer Genomics raised to-date?

As of Jan 1, 2017, Cambridge Cancer Genomics has raised a total of $120k (USD).

Cambridge Cancer Genomics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Treatment
Tags
  • Biotech
  • Data
  • Healthtech